

John E Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8136944/publications.pdf>

Version: 2024-02-01

394
papers

26,069
citations

7551

77
h-index

7136

153
g-index

400
all docs

400
docs citations

400
times ranked

15905
citing authors

#	ARTICLE	IF	CITATIONS
1	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. <i>Blood</i> , 2005, 105, 3051-3057.	0.6	1,574
2	Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia. <i>New England Journal of Medicine</i> , 2004, 351, 2265-2275.	13.9	1,019
3	Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. <i>Blood</i> , 2002, 100, 1611-1618.	0.6	970
4	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. <i>Blood</i> , 2011, 117, 1061-1070.	0.6	926
5	Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated Donors. <i>New England Journal of Medicine</i> , 2001, 344, 1815-1822.	13.9	847
6	Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. <i>Blood</i> , 2005, 105, 1343-1347.	0.6	824
7	Graft-Versus-Host Disease in Children Who Have Received a Cord-Blood or Bone Marrow Transplant from an HLA-Identical Sibling. <i>New England Journal of Medicine</i> , 2000, 342, 1846-1854.	13.9	812
8	Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. <i>Lancet</i> , The, 2007, 369, 1947-1954.	6.3	751
9	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. <i>Lancet Oncology</i> , The, 2010, 11, 653-660.	5.1	532
10	Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. <i>Blood</i> , 2003, 102, 1915-1919.	0.6	397
11	Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2001, 97, 1458-1466.	0.6	396
12	Separation of pluripotent haematopoietic stem cells from spleen colony-forming cells. <i>Nature</i> , 1990, 347, 188-189.	13.7	382
13	Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 387-394.	2.0	367
14	Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. <i>Blood</i> , 2001, 97, 2957-2961.	0.6	361
15	Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. <i>Blood</i> , 2002, 100, 3825-3827.	0.6	356
16	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. <i>Blood</i> , 2016, 127, 1044-1051.	0.6	333
17	Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis Bullosa. <i>New England Journal of Medicine</i> , 2010, 363, 629-639.	13.9	326
18	Massive ex Vivo Expansion of Human Natural Regulatory T Cells (T _{regs}) with Minimal Loss of in Vivo Functional Activity. <i>Science Translational Medicine</i> , 2011, 3, 83ra41.	5.8	326

#	ARTICLE	IF	CITATIONS
19	Hematopoietic Stem-Cell Transplantation in Globoid-Cell Leukodystrophy. <i>New England Journal of Medicine</i> , 1998, 338, 1119-1127.	13.9	308
20	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. <i>Blood</i> , 2018, 131, 2515-2527.	0.6	307
21	Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft. <i>Cell Stem Cell</i> , 2016, 18, 144-155.	5.2	289
22	Trading carbon for food: Global comparison of carbon stocks vs. crop yields on agricultural land. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 19645-19648.	3.3	276
23	Searching for unrelated donor hematopoietic stem cells: Availability and speed of umbilical cord blood versus bone marrow. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 257-260.	2.0	262
24	Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?. <i>Blood</i> , 2003, 101, 4233-4244.	0.6	262
25	Higher Mortality After Allogeneic Peripheral-Blood Transplantation Compared With Bone Marrow in Children and Adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. <i>Journal of Clinical Oncology</i> , 2004, 22, 4872-4880.	0.8	246
26	One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers. <i>New England Journal of Medicine</i> , 2014, 371, 1685-1694.	13.9	246
27	TALEN-based Gene Correction for Epidermolysis Bullosa. <i>Molecular Therapy</i> , 2013, 21, 1151-1159.	3.7	232
28	Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II–III trial. <i>Lancet</i> , The, 2005, 366, 733-741.	6.3	227
29	A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination. <i>Molecular Cell</i> , 2015, 59, 478-490.	4.5	227
30	Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. <i>Blood</i> , 2004, 103, 3226-3229.	0.6	194
31	Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. <i>Blood</i> , 2009, 113, 2410-2415.	0.6	191
32	Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. <i>Blood</i> , 2007, 109, 2256-2262.	0.6	188
33	Umbilical Cord Blood Transplantation for Children with Thalassemia and Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1375-1382.	2.0	188
34	Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. <i>Blood</i> , 2013, 121, 752-758.	0.6	179
35	Results of the Cord Blood Transplantation Study (COBLT): Outcomes of Unrelated Donor Umbilical Cord Blood Transplantation in Pediatric Patients with Lysosomal and Peroxisomal Storage Diseases. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 184-194.	2.0	178
36	Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1461-1468.	2.0	174

#	ARTICLE	IF	CITATIONS
37	Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. <i>Blood</i> , 2009, 113, 1167-1174.	0.6	149
38	Higher Risk of Cytomegalovirus and Aspergillus Infections in Recipients of T Cell-Depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1487-1498.	2.0	148
39	4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies. <i>Human Gene Therapy</i> , 2010, 21, 75-86.	1.4	148
40	A consensus approach to wound care in epidermolysis bullosa. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 904-917.	0.6	148
41	Successful Immune Reconstitution Decreases Leukemic Relapse and Improves Survival in Recipients of Unrelated Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 919-927.	2.0	147
42	Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. <i>Blood</i> , 2009, 113, 5628-5634.	0.6	147
43	Induced Pluripotent Stem Cells from Individuals with Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2011, 131, 848-856.	0.3	139
44	Results of Unrelated Cord Blood Transplant in Fanconi Anemia Patients: Risk Factor Analysis for Engraftment and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1073-1082.	2.0	138
45	Umbilical cord blood transplantation in adults: Results of the prospective cord blood transplantation (COBLT). <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 149-160.	2.0	137
46	Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 40-46.	2.0	134
47	Double umbilical cord blood transplantation. <i>Current Opinion in Immunology</i> , 2006, 18, 571-575.	2.4	134
48	Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 265-273.	2.0	130
49	Sleeping Beauty Transposon-Mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid Malignancies. <i>Molecular Therapy</i> , 2008, 16, 580-589.	3.7	130
50	Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. <i>Lancet Haematology</i> , 2019, 6, e585-e596.	2.2	128
51	Expanding the role of umbilical cord blood transplantation. <i>British Journal of Haematology</i> , 2007, 137, 20-35.	1.2	127
52	A Scheme for Defining Cause of Death and Its Application in the T Cell Depletion Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1469-1476.	2.0	126
53	Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. <i>Blood</i> , 2012, 119, 5591-5598.	0.6	124
54	Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype-identical sibling selected using preimplantation genetic diagnosis. <i>Blood</i> , 2004, 103, 1147-1151.	0.6	123

#	ARTICLE	IF	CITATIONS
55	Stable Long-Term Donor Engraftment following Reduced-Intensity Hematopoietic Cell Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1270-1278.	2.0	120
56	Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 282-289.	2.0	119
57	Serious Infections after Unrelated Donor Transplantation in 136 Children: Impact of Stem Cell Source. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 362-370.	2.0	118
58	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 882-896.	2.0	117
59	Umbilical-cord blood transplantation for the treatment of cancer. <i>Nature Reviews Cancer</i> , 2003, 3, 526-532.	12.8	115
60	Haematopoietic cell transplantation for Fanconi anaemia – when and how?. <i>British Journal of Haematology</i> , 2010, 149, 14-21.	1.2	111
61	Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. <i>British Journal of Haematology</i> , 2009, 147, 246-261.	1.2	108
62	Syndrome of Idiopathic Hyperammonemia after High-Dose Chemotherapy: Review of Nine Cases. <i>American Journal of Medicine</i> , 1988, 85, 662-667.	0.6	106
63	Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 3804-3807.	0.6	103
64	Umbilical Cord Blood Transplantation and Banking. <i>Annual Review of Medicine</i> , 2006, 57, 403-417.	5.0	102
65	Diagnosis of Myelodysplastic Syndrome Among a Cohort of 119 Patients With Fanconi Anemia. <i>American Journal of Clinical Pathology</i> , 2010, 133, 92-100.	0.4	99
66	Cord Blood Transplantation Study (COBLT): Cord Blood Bank Standard Operating Procedures. <i>Stem Cells and Development</i> , 1998, 7, 521-561.	1.0	97
67	Fanconi Anemia Gene Editing by the CRISPR/Cas9 System. <i>Human Gene Therapy</i> , 2015, 26, 114-126.	1.4	94
68	Comparable Long-Term Survival After Unrelated and HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantations for Acute Leukemia in Children Younger Than 18 Months. <i>Journal of Clinical Oncology</i> , 2006, 24, 145-151.	0.8	93
69	Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome. <i>Journal of Clinical Oncology</i> , 2009, 27, 3634-3641.	0.8	92
70	Umbilical Cord Blood Transplantation: The First 20 Years. <i>Seminars in Hematology</i> , 2010, 47, 3-12.	1.8	91
71	Alternative donor hematopoietic cell transplantation for Fanconi anemia. <i>Blood</i> , 2015, 125, 3798-3804.	0.6	90
72	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	2.5	89

#	ARTICLE	IF	CITATIONS
73	Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. <i>American Journal of Transplantation</i> , 2020, 20, 3061-3071.	2.6	89
74	Impact of Cytomegalovirus (CMV) Reactivation after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 215-222.	2.0	84
75	Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 395-399.	2.0	83
76	Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). <i>Blood</i> , 2011, 117, 839-847.	0.6	82
77	Hematopoietic Cell Therapy for Metabolic Disease. <i>Journal of Pediatrics</i> , 2007, 151, 340-346.	0.9	81
78	Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2006, 46, 630-636.	0.8	79
79	Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young Children: The Cord Blood Transplantation Study (COBLT) Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 637-646.	2.0	76
80	Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations. <i>Expert Review of Hematology</i> , 2017, 10, 81-97.	1.0	76
81	Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. <i>Blood Advances</i> , 2018, 2, 909-922.	2.5	76
82	Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix. <i>Lancet, The</i> , 2013, 382, 1214-1223.	6.3	75
83	Cord blood research, banking, and transplantation: achievements, challenges, and perspectives. <i>Bone Marrow Transplantation</i> , 2020, 55, 48-61.	1.3	75
84	Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. <i>British Journal of Haematology</i> , 1997, 96, 749-756.	1.2	72
85	Unrelated cord blood transplantation in children with sickle cell disease: Review of four-center experience. <i>Pediatric Transplantation</i> , 2007, 11, 641-644.	0.5	72
86	Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 287-291.	2.0	72
87	Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine Administration: Implications for Clinical Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1252-1257.	2.0	71
88	Transferrin receptor 1 controls systemic iron homeostasis by fine-tuning hepcidin expression to hepatocellular iron load. <i>Blood</i> , 2019, 133, 344-355.	0.6	71
89	Umbilical cord blood transplantation: current practice and future innovations. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 35-43.	2.0	70
90	Antigen-Specific T-Lymphocyte Function After Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1335-1342.	2.0	70

#	ARTICLE	IF	CITATIONS
91	Anti-HLA Antibodies in Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1704-1708.	2.0	70
92	Patient-Specific Naturally Gene-Reverted Induced Pluripotent Stem Cells in Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1246-1254.	0.3	70
93	Current status of cord blood banking and transplantation in the United States and Europe. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 635-645.	2.0	69
94	HLA-Matched Sibling Hematopoietic Stem Cell Transplantation for Fanconi Anemia: Comparison of Irradiation and Nonirradiation Containing Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1141-1147.	2.0	69
95	Clinical Outcomes of Children Receiving Intensive Cardiopulmonary Support During Hematopoietic Stem Cell Transplant*. <i>Pediatric Critical Care Medicine</i> , 2013, 14, 261-267.	0.2	69
96	Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2002, 116, 716-724.	1.2	68
97	Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes Over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1580-1588.	2.0	68
98	Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 134-140.	2.0	68
99	A comparison of related donor peripheral blood and bone marrow transplants: Importance of late-onset chronic graft-versus-host disease and infections. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 52-59.	2.0	66
100	Does the Hematopoietic Cell Transplantation Specific Comorbidity Index Predict Transplant Outcomes? A Validation Study in a Large Cohort of Umbilical Cord Blood and Matched Related Donor Transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 985-992.	2.0	66
101	Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. <i>American Journal of Medicine</i> , 2001, 110, 339-346.	0.6	65
102	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	0.6	65
103	Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1394-1400.	2.0	63
104	Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 512-518.	2.0	62
105	Effective treatment of β -mannosidosis by allogeneic hematopoietic stem cell transplantation. <i>Journal of Pediatrics</i> , 2004, 144, 569-573.	0.9	62
106	Advances in umbilical cord blood manipulation—from niche to bedside. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 163-174.	12.5	62
107	Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: A comparative clinical analysis. <i>American Journal of Hematology</i> , 2007, 82, 867-872.	2.0	60
108	Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated Marrow and Umbilical Cord Blood versus Marrow from HLA Matched Sibling Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1086-1093.	2.0	60

#	ARTICLE	IF	CITATIONS
109	Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB). <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1145-1152.	2.0	59
110	Umbilical cord blood transplantation: current state of the art. <i>Current Opinion in Oncology</i> , 2002, 14, 160-164.	1.1	58
111	A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 109-116.	2.0	57
112	Early Lymphocyte Recovery and Outcomes after Umbilical Cord Blood Transplantation (UCBT) for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 831-840.	2.0	56
113	Early Reconstitution of NK and $\gamma\delta$ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1152-1162.	2.0	56
114	Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1327-1334.	2.0	54
115	Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies Using a Reduced-Intensity Conditioning Regimen and Third-Party Mesenchymal Stromal Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 581-586.	2.0	54
116	Umbilical cord blood transplantation for myeloid malignancies. <i>Current Opinion in Hematology</i> , 2007, 14, 162-169.	1.2	53
117	Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in α -thalassaemia. <i>British Journal of Haematology</i> , 2014, 164, 384-395.	1.2	53
118	Umbilical Cord and Placental Blood Hematopoietic Stem Cells: Collection, Cryopreservation, and Storage. <i>Stem Cells and Development</i> , 1992, 1, 167-173.	1.0	50
119	Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1653-1662.	2.0	50
120	Cord blood transplantation for adults. <i>Vox Sanguinis</i> , 2006, 91, 195-205.	0.7	49
121	Conditional disruption of mouse HFE2 gene: Maintenance of systemic iron homeostasis requires hepatic but not skeletal muscle hepcidin. <i>Hepatology</i> , 2011, 54, 1800-1807.	3.6	49
122	Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 963-968.	2.0	48
123	Costs of pediatric allogeneic hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2010, 54, 138-143.	0.8	46
124	Stem Cell Gene Therapy for Fanconi Anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting. <i>Molecular Therapy</i> , 2011, 19, 1193-1198.	3.7	45
125	Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 487-492.	2.0	44
126	Guidelines for Cord Blood Unit Selection. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2190-2196.	2.0	44

#	ARTICLE	IF	CITATIONS
127	Late Effects Screening Guidelines after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement From the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects After Pediatric HCT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1422-1428.	2.0	43
128	Homing defect of cultured human hematopoietic cells in the NOD/SCID mouse is mediated by Fas/CD95. <i>Experimental Hematology</i> , 2003, 31, 824-832.	0.2	42
129	Reduced-Intensity Conditioning Regimens for Allogeneic Transplantation in Children with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1237-1244.	2.0	42
130	The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1118-1128.	2.5	42
131	Complement Fragment 3a Priming of Umbilical Cord Blood Progenitors: Safety Profile. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1474-1479.	2.0	41
132	Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. <i>Cytotherapy</i> , 2017, 19, 250-262.	0.3	41
133	Mouse fetal and embryonic liver cells differentiate human umbilical cord blood progenitors into CD56-negative natural killer cell precursors in the absence of interleukin-15. <i>Experimental Hematology</i> , 2008, 36, 598-608.	0.2	40
134	Impact of immune modulation with in vivo T-cell depletion and myeloablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. <i>Blood</i> , 2012, 119, 6155-6161.	0.6	40
135	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings. <i>Blood Advances</i> , 2021, 5, 1425-1436.	2.5	39
136	American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 3668-3689.	2.5	38
137	Umbilical Cord Blood T Cells Express Multiple Natural Cytotoxicity Receptors after IL-15 Stimulation, but Only NKp30 Is Functional. <i>Journal of Immunology</i> , 2008, 181, 4507-4515.	0.4	37
138	Cord blood stem cells. <i>Current Opinion in Hematology</i> , 1997, 4, 413-418.	1.2	36
139	Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 214-222.	2.0	36
140	Survival Differences between Adolescents/Young Adults and Children with B Precursor Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 138-142.	2.0	36
141	Clinical-Scale Selection of Anti-CD3/CD28-Activated T Cells After Transduction with a Retroviral Vector Expressing Herpes Simplex Virus Thymidine Kinase and Truncated Nerve Growth Factor Receptor. <i>Human Gene Therapy</i> , 2002, 13, 979-988.	1.4	35
142	Comprehensive Analysis of Pathogenic Deletion Variants in Fanconi Anemia Genes. <i>Human Mutation</i> , 2014, 35, n/a-n/a.	1.1	35
143	Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 926-933.	2.0	35
144	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35

#	ARTICLE	IF	CITATIONS
145	Keratinocytes from Induced Pluripotent Stem Cells in Junctional Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2013, 133, 562-565.	0.3	33
146	The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 24-29.	2.0	33
147	Rapid Transport and Infusion of Hematopoietic Cells Is Associated with Improved Outcome after Myeloablative Therapy and Unrelated Donor Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 589-596.	2.0	32
148	Reduced-Intensity Conditioning Followed by Related Allografts in Hematologic Malignancies: Long-Term Outcomes Most Successful in Indolent and Aggressive Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1025-1032.	2.0	32
149	Hfe and Hju exhibit overlapping functions for iron signaling to hepcidin. <i>Journal of Molecular Medicine</i> , 2015, 93, 489-498.	1.7	32
150	Iron-Dependent Regulation of Hepcidin in Hju ^{-/-} Mice: Evidence That Hemojuvelin Is Dispensable for Sensing Body Iron Levels. <i>PLoS ONE</i> , 2014, 9, e85530.	1.1	32
151	Concise Review: Transplantation of Human Hematopoietic Cells for Extracellular Matrix Protein Deficiency in Epidermolysis Bullosa. <i>Stem Cells</i> , 2011, 29, 900-906.	1.4	31
152	Early hematopoietic stem cell transplant is associated with favorable outcomes in children with MDS. <i>Pediatric Blood and Cancer</i> , 2013, 60, 705-710.	0.8	31
153	Myeloablative Cord Blood Transplantation in Adults with Acute Leukemia: Comparison of Two Different Transplant Platforms. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1725-1730.	2.0	31
154	Current Knowledge and Priorities for Future Research in Late Effects after Hematopoietic Cell Transplantation for Inherited Bone Marrow Failure Syndromes: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 726-735.	2.0	31
155	Comparable Outcomes after HLA-Matched Sibling and Alternative Donor Hematopoietic Cell Transplantation for Children with Fanconi Anemia and Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 765-771.	2.0	31
156	Current clinical management of Fanconi anemia. <i>Expert Review of Hematology</i> , 2012, 5, 513-522.	1.0	30
157	Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response. <i>British Journal of Haematology</i> , 2014, 166, 209-212.	1.2	30
158	Umbilical Cord Blood Transplants: Current Status and Evolving Therapies. <i>Frontiers in Pediatrics</i> , 2020, 8, 570282.	0.9	30
159	Impact of Long-Term Cryopreservation on Single Umbilical Cord Blood Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 50-54.	2.0	29
160	The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 253-262.	2.0	28
161	Rapidly Growing Mycobacteria among Pediatric Hematopoietic Cell Transplant Patients Traced to the Hospital Water Supply. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 1043-1046.	1.1	28
162	Prevention of Graft-versus-Host Disease by Adoptive T Regulatory Therapy Is Associated with Active Repression of Peripheral Blood Toll-Like Receptor 5 mRNA Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 173-182.	2.0	28

#	ARTICLE	IF	CITATIONS
163	Allogeneic Hematopoietic Cell Transplantation in First Remission Abrogates Poor Outcomes Associated with High-Risk Pediatric Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1021-1025.	2.0	27
164	Second allogeneic hematopoietic cell transplantation for graft failure: Poor outcomes for neutropenic graft failure. <i>American Journal of Hematology</i> , 2015, 90, 892-896.	2.0	27
165	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitorâ€Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2025-2030.	2.0	27
166	Impact of Bone Marrow Hematogones on Umbilical Cord Blood Transplantation Outcomes in Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 930-936.	2.0	26
167	Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. <i>Blood</i> , 2020, 136, 623-626.	0.6	26
168	Implementation of a semiclosed large scale counterflow centrifugal elutriation system. <i>Journal of Clinical Apheresis</i> , 1987, 3, 154-160.	0.7	25
169	More than 10 Years After the First â€Savior Siblingsâ€™: Parental Experiences Surrounding Preimplantation Genetic Diagnosis. <i>Journal of Genetic Counseling</i> , 2013, 22, 594-602.	0.9	25
170	Density separation of umbilical cord blood and recovery of hemopoietic progenitor cells: Implications for cord blood banking. <i>Stem Cells</i> , 1995, 13, 533-540.	1.4	24
171	Allogeneic Hematopoietic Cell Transplantation in Children with Relapsed Acute Lymphoblastic Leukemia Isolated to the Central Nervous System. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 685-692.	2.0	24
172	Activated Notch Supports Development of Cytokine Producing NK Cells Which Are Hyporesponsive and Fail to Acquire NK Cell Effector Functions. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 183-194.	2.0	24
173	Formation of cyclophosphamide specific DNA adducts in hematological diseases. <i>Pediatric Blood and Cancer</i> , 2012, 58, 708-714.	0.8	24
174	Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1714-1721.	2.0	24
175	Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study. <i>Blood</i> , 2009, 114, 663-663.	0.6	24
176	Alternative donor transplantation for acute myeloid leukemia in patients aged â‰¥50 years: young HLA-matched unrelated or haploidentical donor?. <i>Haematologica</i> , 2020, 105, 407-413.	1.7	23
177	Unrelated Donor Bone Marrow Transplantation for Hematological Malignancies-Current Status. <i>Leukemia and Lymphoma</i> , 1996, 23, 221-226.	0.6	22
178	Immune Functions of Cord Blood Cells before and after Transplantation. <i>Stem Cells and Development</i> , 1996, 5, 157-160.	1.0	21
179	In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2173-2179.	2.0	21
180	Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. <i>Blood Advances</i> , 2020, 4, 1284-1295.	2.5	21

#	ARTICLE	IF	CITATIONS
181	Radiotherapy of CD19 Expressing Daudi Tumors in Nude Mice with Yttrium-90-Labeled Anti-CD19 Antibody. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 11-23.	0.7	20
182	Suppressor Function of Umbilical Cord Blood-Derived CD4+CD25+ T-Regulatory Cells Exposed to Graft-versus-Host Disease Drugs. <i>Transplantation</i> , 2006, 82, 23-29.	0.5	20
183	Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls. <i>Experimental Dermatology</i> , 2012, 21, 896-900.	1.4	20
184	Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa. <i>Pediatric Research</i> , 2018, 83, 318-324.	1.1	20
185	In Vivo Selection of Antifolate-Resistant Transgenic Hematopoietic Stem Cells in a Murine Bone Marrow Transplant Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 50-56.	1.3	19
186	Fatal Hemorrhage from Androgen-Related Hepatic Adenoma After Hematopoietic Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 16-18.	0.3	18
187	Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2014, 55, 358-364.	0.6	18
188	The Minnesota Molecular and Cellular Therapeutics Facility: A State-of-the-Art Biotherapeutics Engineering Laboratory. <i>Transfusion Medicine Reviews</i> , 2005, 19, 217-228.	0.9	17
189	Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. <i>Blood Advances</i> , 2021, 5, 4064-4072.	2.5	17
190	Karyotype at relapse following allogeneic bone marrow transplantation for chronic myelogenous leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1992, 61, 183-192.	1.0	16
191	Should double cord blood transplants be the preferred choice when a sibling donor is unavailable?. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 551-555.	0.7	15
192	Transplantation of CCR5 ^{Δ32} Homozygous Umbilical Cord Blood in a Child With Acute Lymphoblastic Leukemia and Perinatally Acquired HIV Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy090.	0.4	15
193	Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation. <i>Blood Advances</i> , 2019, 3, 230-236.	2.5	15
194	Density Separation and Cryopreservation of Umbilical Cord Blood Cells: Evaluation of Recovery in Short- and Long-Term Cultures. <i>Acta Haematologica</i> , 1996, 95, 171-175.	0.7	14
195	Ex vivo expansion of umbilical cord blood hemopoietic stem and progenitor cells. <i>Experimental Hematology</i> , 2004, 32, 412-413.	0.2	14
196	Leukodystrophy and Gene Therapy with a Dimmer Switch. <i>New England Journal of Medicine</i> , 2011, 364, 572-573.	13.9	14
197	Monocyte Subpopulation Recovery as Predictors of Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 883-890.	2.0	14
198	High Incidence of Hematopoietic Stem Cell Mosaicism in Fanconi Anemia.. <i>Blood</i> , 2006, 108, 993-993.	0.6	14

#	ARTICLE	IF	CITATIONS
199	Transplant Outcomes in Acute Leukemia (I). <i>Seminars in Hematology</i> , 2010, 47, 46-50.	1.8	13
200	Bone Mineral Density in Children with Fanconi Anemia after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 894-899.	2.0	13
201	Endocrinopathies, Bone Health, and Insulin Resistance in Patients with Fanconi Anemia after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1487-1492.	2.0	13
202	Mouse models of hereditary hemochromatosis do not develop early liver fibrosis in response to a high fat diet. <i>PLoS ONE</i> , 2019, 14, e0221455.	1.1	13
203	Characterization of the Natural Suppressor Cell Population in Adult Rat Bone Marrow. <i>Journal of Leukocyte Biology</i> , 1988, 43, 279-287.	1.5	12
204	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	2.5	12
205	A Biologic Velcro Patch. <i>New England Journal of Medicine</i> , 2015, 372, 382-384.	13.9	11
206	Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 825-833.	2.0	11
207	The role of peripheral nerve signaling in endometriosis. <i>FASEB BioAdvances</i> , 2021, 3, 802-813.	1.3	11
208	No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. <i>Blood</i> , 2012, 120, 359-359.	0.6	11
209	StemRegenin-1 (SR1) Expansion Culture Abrogates the Engraftment Barrier Associated with Umbilical Cord Blood Transplantation (UCBT). <i>Blood</i> , 2014, 124, 728-728.	0.6	11
210	PREVENTION OF GRAFT FAILURE BY CYCLOSPORINE IN RATS RECEIVING LYMPHOCYTE-DEPLETED MHC-MISMATCHED BONE MARROW. <i>Transplantation</i> , 1992, 53, 624-627.	0.5	10
211	First phase insulin release and glucose tolerance in children with Fanconi anemia after hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2009, 53, 191-196.	0.8	10
212	Growth hormone treatment of patients with Fanconi Anemia after hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1142-1143.	0.8	10
213	Toxic Epidermal Necrolysis in Recessive Dystrophic Epidermolysis Bullosa following Bone Marrow Transplantation. <i>Journal of Pediatrics</i> , 2016, 173, 242-244.	0.9	10
214	Management of Risks From Water and Ice From Ice Machines for the Very Immunocompromised Host: A Process Improvement Project Prompted by an Outbreak of Rapidly Growing Mycobacteria on a Pediatric Hematopoietic Stem Cell Transplant (Hsct) Unit. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 792-800.	1.0	10
215	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 126-133.	2.0	10
216	Neoadjuvant Chemotherapy with Reduced-Dose Carboplatin and Gemcitabine for Non-small Cell Lung Cancer in a Patient with Fanconi Anemia. <i>Journal of Thoracic Oncology</i> , 2008, 3, 447-450.	0.5	9

#	ARTICLE	IF	CITATIONS
217	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1790-1795.	2.0	9
218	An Exploratory Analysis of Mitochondrial Haplotypes and Allogeneic Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 81-88.	2.0	9
219	Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1884-1889.	2.0	9
220	Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. <i>Bone Marrow Transplantation</i> , 2021, 56, 1238-1247.	1.3	9
221	Preimplantation Testing to Produce an HLA-Matched Donor Infant. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 803.	3.8	9
222	Non-Myeloablative (NMA) Umbilical Cord Blood Transplantation (UCBT): Promising Disease-Free Survival in 95 Consecutive Patients.. <i>Blood</i> , 2005, 106, 559-559.	0.6	9
223	Conception to obtain hematopoietic stem cells. <i>Hastings Center Report</i> , 2002, 32, 34-40.	0.7	9
224	Hematopoietic cell transplantation for congenital bone marrow failure. <i>Current Opinion in Oncology</i> , 2005, 17, 106-113.	1.1	8
225	Recent Developments in Cell-based Immune Therapy for Neuroblastoma. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 134-139.	2.1	8
226	Umbilical Cord Transplantation: State of the Art 2010. <i>Seminars in Hematology</i> , 2010, 47, 1-2.	1.8	8
227	Safety and Exploratory Efficacy Of Ex Vivo Expanded Umbilical Cord Blood (UCB) Hematopoietic Stem and Progenitor Cells (HSPC) Using Cytokines and Stem-Regenin 1 (SR1): Interim Results Of a Phase 1/2 Dose Escalation Clinical Study. <i>Blood</i> , 2013, 122, 698-698.	0.6	8
228	Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial.. <i>Blood</i> , 2004, 104, 1825-1825.	0.6	8
229	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial. <i>Blood</i> , 2017, 130, 847-847.	0.6	8
230	Comparison of molecular and cytogenetic methods in the evaluation of engraftment following allogeneic bone marrow transplantation. <i>Cancer Genetics and Cytogenetics</i> , 1991, 55, 181-190.	1.0	7
231	Umbilical Cord Blood Stem Cell Transplantation: Current Status and Future Prospects (1992). <i>Stem Cells and Development</i> , 1993, 2, 225-228.	1.0	7
232	Strategies for More Rapid Translation of Cellular Therapies for Children: A US Perspective. <i>Pediatrics</i> , 2013, 132, 351-358.	1.0	7
233	Paternal or Maternal Uniparental Disomy of Chromosome 16 Resulting in Homozygosity of a Mutant Allele Causes Fanconi Anemia. <i>Human Mutation</i> , 2016, 37, 465-468.	1.1	7
234	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. <i>Cytotherapy</i> , 2021, 23, 704-714.	0.3	7

#	ARTICLE	IF	CITATIONS
235	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. <i>Bone Marrow Transplantation</i> , 2021, 56, 1373-1380.	1.3	7
236	Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Leukemia: Risks and Benefits of Umbilical Cord Blood (CB) vs. Bone Marrow (BM).. <i>Blood</i> , 2005, 106, 302-302.	0.6	7
237	Dyskeratosis Congenita: Low Regimen-Related Toxicity Following Hematopoietic Cell Transplantation (HCT) Using a Reduced Intensity Conditioning Regimen.. <i>Blood</i> , 2007, 110, 2005-2005.	0.6	7
238	'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15R α -Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy. <i>Blood</i> , 2015, 126, 1957-1957.	0.6	7
239	Expression of α IIb β 3 Integrin (GPIIb-IIIa) in Myeloid Cell Lines and Normal CD34+/CD33+ Bone Marrow Cells. <i>Blood Cells, Molecules, and Diseases</i> , 1997, 23, 361-376.	0.6	6
240	Fludarabine Pharmacokinetics in Nonmyeloablative Hematopoietic Cell Transplantation (HCT): Association with Engraftment and Neurotoxicity.. <i>Blood</i> , 2005, 106, 3673-3673.	0.6	6
241	Kinetics of Chimerism and Unit Predominance After Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2010, 116, 225-225.	0.6	6
242	UCB and atmospheric noise. <i>Blood</i> , 2010, 115, 754-755.	0.6	5
243	Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. <i>Haematologica</i> , 2016, 101, e348-e351.	1.7	5
244	Elevations in serum alpha fetoprotein levels in patients with Fanconi anaemia. <i>British Journal of Haematology</i> , 2019, 184, 1032-1035.	1.2	5
245	Low 5-year health care burden after umbilical cord blood transplantation. <i>Blood Advances</i> , 2021, 5, 853-860.	2.5	5
246	Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2826-2833.	1.3	5
247	Non-Myeloablative Umbilical Cord Blood Transplantation (UCBT): Low Transplant-Related Mortality in 59 High-Risk Adults.. <i>Blood</i> , 2004, 104, 825-825.	0.6	5
248	Matched Sibling Donor Hematopoietic Cell Transplantation for Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen Can Lead To Stable Long Term Engraftment.. <i>Blood</i> , 2005, 106, 3172-3172.	0.6	5
249	Thymic Shielding (TS) in Recipients of Total Body Irradiation (TBI) and Alternative Donor Hematopoietic Stem Cell Transplant (AD-HSCT): Reduced Risk of Opportunistic Infection in Patients with Fanconi Anemia (FA).. <i>Blood</i> , 2006, 108, 3134-3134.	0.6	5
250	Single Versus Double Umbilical Cord Blood Transplantation (UCBT): Higher Risk of Acute Graft-Versus-Host Disease (GVHD) but Lower Transplant Related Mortality (TRM) in Recipients of Double UCBT.. <i>Blood</i> , 2006, 108, 435-435.	0.6	5
251	Umbilical Cord Blood Transplant after Reduced Intensity Conditioning Provides Outcomes Comparable HLA-Matched Siblings for Patients with High Risk and Advanced Acute Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 606-606.	0.6	5
252	Reduced Relapse and Similar Progression-Free Survival After Double Umbilical Cord Blood Transplantation (DUCBT): Comparison of Outcomes Between Sibling, Unrelated Adult and Unrelated DUCB Hematopoietic Stem Cell (HSC) Donors.. <i>Blood</i> , 2009, 114, 662-662.	0.6	5

#	ARTICLE	IF	CITATIONS
253	Dose Dependent Enhancement Of Neutrophil Recovery By Infusion Of Notch Ligand Ex Vivo Expanded Cord Blood Progenitors: Results Of a Multi-Center Phase I Trial. <i>Blood</i> , 2013, 122, 297-297.	0.6	5
254	Umbilical Cord and Placental Blood Transplantation: Analysis of the Clinical Results. <i>Stem Cells and Development</i> , 1993, 2, 265-268.	1.0	4
255	Designer babies - are they a reality yet?. <i>Reproductive BioMedicine Online</i> , 2000, 1, 77.	1.1	4
256	Novel conditioning regimens and nonmyeloablative stem cell transplants. <i>Current Opinion in Pediatrics</i> , 2002, 14, 17-22.	1.0	4
257	One-Unit versus Two-Unit Cord-Blood Transplantation. <i>New England Journal of Medicine</i> , 2015, 372, 287-288.	13.9	4
258	Cord blood 2.0: state of the art and future directions in transplant medicine. <i>Blood Research</i> , 2019, 54, 7-9.	0.5	4
259	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS).. <i>Blood</i> , 2005, 106, 2064-2064.	0.6	4
260	Umbilical Cord Blood (UCB) Transplantation after Non-Myeloablative (NMA) Conditioning for Advanced Follicular Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia: Low Transplant-Related Mortality and High Progression-Free Survival.. <i>Blood</i> , 2005, 106, 2900-2900.	0.6	4
261	Use of Peripheral Blood Grafts Is Associated with Increased Acute and Chronic Graft-Versus-Host Disease without Improved Survival after Unrelated Donor Transplantation.. <i>Blood</i> , 2005, 106, 443-443.	0.6	4
262	Effect of Stem Cell Source on Transplant Outcomes in Adults with Acute Leukemia: A Comparison of Unrelated Bone Marrow (BM), Peripheral Blood (PB) and Cord Blood (CB). <i>Blood</i> , 2008, 112, 151-151.	0.6	4
263	Favorable Leukemia-Free Survival (LFS) for Adults and Children Undergoing Myeloablative Umbilical Cord Blood (UCB) Transplantation with Cyclophosphamide (CY), Fludarabine (FLU) and Total Body Irradiation (TBI): A Single Center Analysis of 194 Patients.. <i>Blood</i> , 2008, 112, 1957-1957.	0.6	4
264	Adoptive Transfer of Umbilical Cord Blood (UCB)-Derived Regulatory T Cells (Tregs) to Recipients of Nonmyeloablative Unrelated Double UCB Transplantation.. <i>Blood</i> , 2009, 114, 513-513.	0.6	4
265	Immune Reconstitution after Umbilical Cord Blood Versus Peripheral Blood Progenitor Cell Transplantation in Adults Following Myeloablative Conditioning. <i>Blood</i> , 2016, 128, 2246-2246.	0.6	4
266	Phase 2 Trials with Mgta-456, Single Cord Blood Units (CBU) Expanded with an Aryl Hydrocarbon Receptor (AHR) Antagonist, Demonstrate Uniform Engraftment and Rapid Hematopoietic Recovery in Patients Following Myeloablative or Non-Myeloablative Conditioning. <i>Blood</i> , 2017, 130, 662-662.	0.6	4
267	Unrelated Cord Blood Transplantation after Reduced Intensity Conditioning (RIC) in Adults with Hematological Malignancy. An EBMT-Eurocord-Netcord, Soci�t� Franc�aise de Greffe de Moelle et de Th�rapie Cellulaire and University of Minnesota Collaborative Study.. <i>Blood</i> , 2007, 110, 2027-2027.	0.6	4
268	Validation of Minnesota Acute GVHD Risk Score and Identification of New Factors Associated with Initial Response to Steroids: Not All GVHD Is Created Equal. <i>Blood</i> , 2018, 132, 67-67.	0.6	4
269	Less Acute Graft-Versus-Host Disease with Higher Mycophenolate Dose in. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S28-S29.	2.0	3
270	Establishing the UCB graft potentiality. <i>Blood</i> , 2016, 127, 2272-2274.	0.6	3

#	ARTICLE	IF	CITATIONS
271	Mgta-456, an Aryl Hydrocarbon Receptor (AHR) Antagonist Based Expansion of CD34+ Hematopoietic Stem Cells (HSC), Permits Selection of Better HLA Matched Cord Blood Units (CBUs) and Promotes Faster Neutrophil Recovery and Uniform Engraftment with Potentially Less Acute Graft-Vs-Host Disease (GVHD). <i>Blood</i> , 2019, 134, 804-804.	0.6	3
272	Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience.. <i>Blood</i> , 2005, 106, 2044-2044.	0.6	3
273	Alternate Donor HCT for Fanconi Anemia (FA): Results of a Total Body Irradiation (TBI) Dose De-Escalation Study. <i>Blood</i> , 2008, 112, 2998-2998.	0.6	3
274	Similar Survival after Umbilical Cord Blood (UCB) and HLA-Matched Adult Donor Transplantation By Disease Risk Index (DRI) Assignment. <i>Blood</i> , 2015, 126, 4375-4375.	0.6	3
275	Monocyte Subpopulation Recovery and Outcomes Following Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 2232-2232.	0.6	3
276	Alternative Donor Hematopoietic Cell Transplantation In 94 Patients with Fanconi Anemia at the University of Minnesota. <i>Blood</i> , 2010, 116, 3526-3526.	0.6	3
277	A new route to the stem-cell niche. <i>Lancet Oncology</i> , The, 2008, 9, 812-814.	5.1	2
278	The Evolution of Gene Transfer, Gene Therapy, and the RAC: IOM Recommendations to the NIH Director. <i>Molecular Therapy</i> , 2014, 22, 685-686.	3.7	2
279	Second Allogeneic Hematopoietic Cell Transplantation for Graft Failure: Poorer Outcomes for Neutropenic Graft Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S166-S167.	2.0	2
280	Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S55.	2.0	2
281	Comparison of Haploidentical Related Donor with Post-Transplant Cyclophosphamide (PTCy) and Umbilical Cord Blood (UCB) Transplantation after Myeloablative Conditioning for Hematological Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S291.	2.0	2
282	Mgta-456 Cell Therapy in Inherited Metabolic Disease (IMD) Yields Rapid and Durable Long-Term Improvement of Disease-Specific Outcomes in a Phase 2 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S19.	2.0	2
283	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. <i>Blood</i> , 2018, 132, 71-71.	0.6	2
284	Successful Remission of Poor Prognosis AML after Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells.. <i>Blood</i> , 2004, 104, 260-260.	0.6	2
285	Hematopoietic Cell Transplantation in Fanconi Anemia Patients with Biallelic BRCA2 Mutations.. <i>Blood</i> , 2004, 104, 2838-2838.	0.6	2
286	Unrelated Donor Transplantation for Fanconi Anemia: Analysis of Prognostic Factors Impacting Engraftment and Survival.. <i>Blood</i> , 2004, 104, 824-824.	0.6	2
287	SNX5, a Novel Gene Linked to Fanconi Anemia Causes Hematopoietic Failure When Knocked down in Zebrafish.. <i>Blood</i> , 2005, 106, 183-183.	0.6	2
288	Negative Impact of KIR-Ligand Mismatch on Transplant-Related Mortality (TRM) in Umbilical Cord Blood Transplant (UCBT) Recipients.. <i>Blood</i> , 2005, 106, 2041-2041.	0.6	2

#	ARTICLE	IF	CITATIONS
289	Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Leukemia: Risks and Benefits of Umbilical Cord Blood (CB) Versus HLA A, B, C, DRB1 Allele-Matched Bone Marrow (BM).. Blood, 2006, 108, 434-434.	0.6	2
290	CMV Reactivation is Associated with Reduced Relapse Risk, Better Disease-Free Survival and Expansion of Adaptive NK Cells after Reduced Intensity Hematopoietic Cell Transplantation. Blood, 2014, 124, 668-668.	0.6	2
291	High Peripheral Blood Stem Cell (PBSC) CD34+ Cell Dose Increases the Risk of Chronic Gvhd after Human Leukocyte Antigen (HLA) Matched Sibling Transplantation. Blood, 2016, 128, 5877-5877.	0.6	2
292	ABO Mismatch Adversely Affects GvHD In Recipients of HLA Matched Unrelated Marrow or Peripheral Blood but Not Single or Double Umbilical Cord Blood Transplants. Blood, 2010, 116, 226-226.	0.6	2
293	The Epic Race to Immune Reconstitution. Biology of Blood and Marrow Transplantation, 2012, 18, 493-494.	2.0	1
294	Sirolimus/Mycophenolate Mofetil (MMF): Effective Calcineurin Inhibitor-Free GVHD Prophylaxis for Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S305.	2.0	1
295	Single Cord Blood Units (CBU) Expanded with an Aryl Hydrocarbon Receptor (AHR) Antagonist, Demonstrate Uniform Engraftment and Rapid Hematopoietic Recovery. Biology of Blood and Marrow Transplantation, 2018, 24, S24.	2.0	1
296	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl®): A Phase I Study. Biology of Blood and Marrow Transplantation, 2019, 25, S240-S241.	2.0	1
297	Mgta-456 Contains Large Numbers of CD34+CD90+ Hematopoietic Stem Cells (HSC) Which Contain the NSG Engraftment Activity and Correlate with Time to Neutrophil Recovery Following Transplant into Patients with Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2019, 25, S2-S3.	2.0	1
298	Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. European Journal of Haematology, 2021, 106, 205-212.	1.1	1
299	Reduced Intensity Conditioned Bone Marrow Transplant with Post-Transplant Cyclophosphamide and Donor-Derived Mesenchymal Stromal Cell Infusions for Recessive Dystrophic Epidermolysis Bullosa. Blood, 2018, 132, 2165-2165.	0.6	1
300	First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 2112-2112.	0.6	1
301	Higher Cell Dose and CD34+ Content Improves Engraftment Following Unrelated Donor Cord Blood Transplantation (CBT): A Report of the National Marrow Donor Program (NMDP) Cord Blood (CB) Experience.. Blood, 2004, 104, 975-975.	0.6	1
302	Increased Risk of Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) after Anti-Thymocyte Globulin (ATG) Non-Myeloablative (NMA) Conditioning for Umbilical Cord Blood Transplantation (UCBT).. Blood, 2005, 106, 3235-3235.	0.6	1
303	Prognostic Factors in Patients with Fanconi Anemia (FA) after Alternate Donor (AD) Hematopoietic Cell Transplantation (HCT).. Blood, 2005, 106, 564-564.	0.6	1
304	Cord Blood Transplantation from Unrelated Donors for Adults with Advanced Lymphoid Malignancies - A Eurocord-Netcord Group/EBMT-LWP Study.. Blood, 2007, 110, 2025-2025.	0.6	1
305	Reduced Intensity Conditioning (RIC) Transplantation In Acute Leukemia: The Effect of Source of Unrelated Donor Stem Cells on Outcomes. Blood, 2010, 116, 908-908.	0.6	1
306	Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2. Blood, 2012, 120, 346-346.	0.6	1

#	ARTICLE	IF	CITATIONS
307	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2015, 126, 2022-2022.	0.6	1
308	Mucocutaneous Engraftment and Type VII Collagen (C7) Replacement after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). <i>Blood</i> , 2015, 126, 402-402.	0.6	1
309	In Vitro Induction of Human Regulatory T-Cells (iTregs) Using Conditions of Low Tryptophan Plus Kynurenines. <i>Blood</i> , 2016, 128, 1229-1229.	0.6	1
310	Umbilical Cord Blood (UCB) Transplantation in Children with Acute Leukemia: Impact of Conditioning Regimen on Transplant Outcomes. <i>Blood</i> , 2016, 128, 1231-1231.	0.6	1
311	Double Unit Myeloablative Umbilical Cord Blood (UCB) Transplantation in Adults & Adolescents: High Incidence of Engraftment and Low Transplant-Related Mortality.. <i>Blood</i> , 2004, 104, 826-826.	0.6	1
312	Rapid Transport and Infusion of Hematopoietic Stem Cells Can Improve Outcome after Unrelated Donor Transplant.. <i>Blood</i> , 2007, 110, 3063-3063.	0.6	1
313	Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia.. <i>Blood</i> , 2012, 120, 3081-3081.	0.6	1
314	Preliminary Phase 2 Results Demonstrate Engraftment with Minimal Neutropenia with MGTA-456, a CD34+ Expanded Cord Blood (CB) Product in Patients Transplanted for Inherited Metabolic Disorders (IMD). <i>Blood</i> , 2018, 132, 3467-3467.	0.6	1
315	Gene Therapy for Fanconi Anemia [Group A]: Interim Results of RP-L102 Clinical Trials. <i>Blood</i> , 2021, 138, 3968-3968.	0.6	1
316	Etiologies of hearing loss in Fanconi Anemia. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2022, 155, 111068.	0.4	1
317	Possible role of <i>Campylobacter pylori</i> in idiopathic hyperammonemia. <i>American Journal of Medicine</i> , 1989, 87, 249-250.	0.6	0
318	Use of Cord Blood Progenitor Cells as an Alternative for Bone Marrow Transplantation. <i>Vox Sanguinis</i> , 1998, 75, 158-160.	0.7	0
319	First Report of Donor Cell Leukemia After Umbilical Cord Blood Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 462.	0.3	0
320	4: Double Umbilical Cord Transplants (UCBT) with Myeloablative or Reduced Intensity Conditioning Regimens (RIC). <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1218-1219.	2.0	0
321	Reply to Vermeulen and Wollenberg: Distinguishing food security and crop yields. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E31-E31.	3.3	0
322	Bone Marrow Is the Preferred Graft for Allogeneic Hematopoietic Cell Transplantation (HCT) in Severe Epidermolysis Bullosa. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S166.	2.0	0
323	Similar Survival in Patients with Acute Myeloid Leukemia Relapsing After Matched Related Donor and Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S113.	2.0	0
324	High-Resolution Donor-Recipient HLA Matching Does Not Influence Acute or Chronic Gvhd in Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S140.	2.0	0

#	ARTICLE	IF	CITATIONS
325	Preservation of Ovarian Function after Hematopoietic Cell Transplantation (HCT): More Possible Than We Thought?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S178.	2.0	0
326	Prevention of Acute GVHD by Ex Vivo Expanded Umbilical Cord Blood Derived Regulatory T Cells (Treg). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S55-S56.	2.0	0
327	FDG-PET Interpreted By Deauville Criteria Prior to Allogeneic Transplantation Predicts Outcomes in Patients with Relapsed or Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S86-S87.	2.0	0
328	Impact of Delayed Infusion Time in Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 836-839.	2.0	0
329	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/ II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S57.	2.0	0
330	Robust Progenitor T-Cell Production From Human Hematopoietic Progenitor Cell Expanded with Stemregenin-1. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S425-S426.	2.0	0
331	Robust Engraftment with Mgta-456, a CD34+ Expanded Cell Therapy Product in Patients with Inherited Metabolic Disorders (IMD): Preliminary Phase 2 Trial Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S91-S92.	2.0	0
332	Mgta-456, a Cell Therapy Utilizing Expansion of CD34+ Hematopoietic Stem Cells (HSC), Improves HLA Matching for Adult Recipients, Promotes Faster Hematopoietic Recovery and Enables Uniform Engraftment with Less Acute Graft-Vs-Host Disease (GVHD). <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S205-S206.	2.0	0
333	Successful Allogeneic Hematopoietic Stem Cell Transplantation in Mice Mediated By Well-Tolerated Conditioning Regimens Based on CD45-Targeted Antibody Drug Conjugate: Implications for Haplo Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S160.	2.0	0
334	Defective Anti-Bacterial Carbohydrate Antibody Production after Unrelated HSC Transplantation.. <i>Blood</i> , 2004, 104, 5060-5060.	0.6	0
335	Establishment of the NMDP Cord Blood Banking Network.. <i>Blood</i> , 2004, 104, 5190-5190.	0.6	0
336	Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.. <i>Blood</i> , 2004, 104, 1817-1817.	0.6	0
337	Prevalence of Microbially Contaminated Hematopoietic Stem Cell Products.. <i>Blood</i> , 2004, 104, 2228-2228.	0.6	0
338	Clonal Evolution of Fanconi Anemia (FA) Stem Cells Results from Clonal Adaptation and Clonal Selection. A Report from the International Fanconi Anemia Transcriptome Consortium.. <i>Blood</i> , 2004, 104, 3416-3416.	0.6	0
339	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. <i>Blood</i> , 2004, 104, 2148-2148.	0.6	0
340	The Impact of Variability among Banks on the Quality of Umbilical Cord Blood for Transplantation.. <i>Blood</i> , 2004, 104, 2861-2861.	0.6	0
341	Results of Unrelated Cord Blood Transplants in Fanconi Anemia.. <i>Blood</i> , 2004, 104, 2145-2145.	0.6	0
342	Hematopoietic Stem Cell Transplantation (HSCT) as Curative Therapy for Fanconi Anemia (FA) Patients with Acute Leukemia or Advanced Myelodysplasia (MDS).. <i>Blood</i> , 2005, 106, 5464-5464.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Antigen-Specific T Lymphocyte Function Following Unrelated Cord Blood Transplantation (UCBT).. Blood, 2005, 106, 3032-3032.	0.6	0
344	Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Isolated CNS Relapse.. Blood, 2005, 106, 2745-2745.	0.6	0
345	NK Cell KIR Reconstitution after Allogeneic Hematopoietic Cell Transplant (HCT) Is Affected by T Cell Number and Function.. Blood, 2005, 106, 1406-1406.	0.6	0
346	Immunotherapy of EBV Post Solid Organ Transplantation Lymphoproliferative Disease with Genetically Engineered Haploidentical T Cells.. Blood, 2005, 106, 5541-5541.	0.6	0
347	Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell Transplantation (SCT).. Blood, 2006, 108, 2999-2999.	0.6	0
348	Hematopoietic Cell Transplantation as Therapy for Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia with and without CNS Involvement.. Blood, 2006, 108, 3110-3110.	0.6	0
349	Sleeping Beauty (SB) Transposon Mediated Umbilical Cord Blood (UCB) T Cell Therapy for Refractory Acute Lymphoblastic Leukemia (ALL).. Blood, 2006, 108, 722-722.	0.6	0
350	Umbilical Cord Blood Transplantation (UCBT) at the University of Minnesota: Impact of Double Unit and Fludarabine on Engraftment after Myeloablative Conditioning.. Blood, 2006, 108, 3116-3116.	0.6	0
351	Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).. Blood, 2006, 108, 2636-2636.	0.6	0
352	Reduced Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor.. Blood, 2007, 110, 331-331.	0.6	0
353	Umbilical Cord Blood T Cells Express the Natural Cytotoxicity Receptors, NKp30, NKp44 and NKp46 after IL-15 Stimulation, but Only NKp30 Is Functional.. Blood, 2007, 110, 61-61.	0.6	0
354	The Predictive Value of the Hematopoietic Cell Transplantation (HCT)-Specific Comorbidity Index (CI) in Recipients of Umbilical Cord Blood (UCB) Transplantation.. Blood, 2007, 110, 5065-5065.	0.6	0
355	Encouraging Results of Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation for the Treatment of Advanced Lymphoid Malignancies.. Blood, 2007, 110, 2028-2028.	0.6	0
356	Alternate Donor HSCT for Fanconi Anemia (FA): Results of a Total Body Irradiation (TBI) Dose De-Escalation Study.. Blood, 2007, 110, 5071-5071.	0.6	0
357	Myelodysplastic Syndrome in Fanconi Anemia: Morphologic and Cytogenetic Findings Are Strongly Correlated.. Blood, 2007, 110, 2458-2458.	0.6	0
358	Graft Composition and Outcomes in Unrelated Donor Transplantation.. Blood, 2007, 110, 3065-3065.	0.6	0
359	Effect of Graft Engineering and Post-Transplantation Immunosuppression Regimen on Immunophenotypic Recovery in Recipients of Unrelated Donor Bone Marrow (T-Cell Depletion Trial) in a Multicenter Randomized Phase II-III Trial.. Blood, 2007, 110, 1067-1067.	0.6	0
360	Prolonged Survival in Adults with Acute Lymphoblastic Leukemia (ALL) Following Reduced Intensity Conditioning and Allogeneic Transplantation. Blood, 2008, 112, 4415-4415.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Negative Effect of KIR Alloreactivity in Recipients of Umbilical Cord Blood Transplantation Depends on Transplantation Conditioning Intensity. <i>Blood</i> , 2008, 112, 152-152.	0.6	0
362	High Probability of Survival after Related and Alternate Donor Hematopoietic Cell Transplantation for Pediatric Patients with High Risk AML Using a Fludarabine Based Preparative Regimen. <i>Blood</i> , 2008, 112, 4430-4430.	0.6	0
363	Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2008, 112, 1116-1116.	0.6	0
364	Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2008, 112, 795-795.	0.6	0
365	First Use of Allogeneic Stem Cells in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: Demonstration of Biochemical and Clinical Improvement.. <i>Blood</i> , 2009, 114, 660-660.	0.6	0
366	Impact of Graft Source on Immune Recovery: Comparisons Between Unrelated Umbilical Cord Blood (UCB), HLA Matched Sibling (Sib) Donor and Autologous (Auto) Hematopoietic Stem Cells.. <i>Blood</i> , 2010, 116, 3731-3731.	0.6	0
367	Chronic Graft-Versus-Host Disease and Its Association with Treatment-Related Mortality, Relapse, Leukemia-Free and Overall Survival After Umbilical Cord Blood Transplantation (UCBT) in Children and Adolescents with Acute Leukemia. <i>Blood</i> , 2010, 116, 213-213.	0.6	0
368	Donor-Derived Myelodysplastic Syndrome and Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Incidence, Natural History and Treatment Response. <i>Blood</i> , 2010, 116, 1306-1306.	0.6	0
369	Reduced Intensity Versus Myeloablative Conditioning in Adults with Acute Myeloid Leukemia Transplanted with Umbilical Cord Blood. <i>Blood</i> , 2010, 116, 3531-3531.	0.6	0
370	Unrelated Cord Blood Transplantation (UCBT) in Adult and Pediatric Acute Lymphoblastic Leukemia: Impact of Minimal Residual Disease on Relapse and Survival,. <i>Blood</i> , 2011, 118, 4114-4114.	0.6	0
371	The Impact of Bone Marrow Hematogones on Umbilical Cord Blood Transplant Outcomes in Acute Myeloid Leukemia Patients,. <i>Blood</i> , 2011, 118, 4148-4148.	0.6	0
372	Hematopoietic Cell Transplantation for FA Patients with Acute Leukemia or Advanced MDS,. <i>Blood</i> , 2011, 118, 4146-4146.	0.6	0
373	Elevated Absolute Lymphocyte Counts Following Acute Graft Vs. Host Disease Treatment Is Associated with Therapeutic Responses and Lower Non-Relapse Mortality Following Umbilical Cord Blood Transplant,. <i>Blood</i> , 2011, 118, 4085-4085.	0.6	0
374	Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes. <i>Blood</i> , 2012, 120, 965-965.	0.6	0
375	Increased Relapse Associated with Mixed Donor-Donor Chimerism Following Double Umbilical Cord Blood Transplantation (dUCBT). <i>Blood</i> , 2012, 120, 358-358.	0.6	0
376	A Randomized Trial of One Vs. Two Doses of Influenza Vaccine Following Allogeneic Transplantation. <i>Blood</i> , 2012, 120, 1896-1896.	0.6	0
377	Allele Level HLA Matching On Outcomes After Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies: Stronger Graft Vs. Leukemia with HLA Mismatch. <i>Blood</i> , 2012, 120, 1976-1976.	0.6	0
378	Impact of Umbilical Cord Blood (UCB) T Regulatory Cells (Tregs) On Infection Risk Early After UCB Transplant. <i>Blood</i> , 2012, 120, 4188-4188.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Hematopoietic Cell Transplantation (HCT) For Fanconi Anemia (FA): Comparable Outcomes Regardless Of Stem Cell Source. <i>Blood</i> , 2013, 122, 3706-3706.	0.6	0
380	Higher CSA Levels After Umbilical Cord Blood Transplant For Acute Leukemia Result In Improved Survival. <i>Blood</i> , 2013, 122, 2097-2097.	0.6	0
381	Early NK Cell Proliferation After Umbilical Cord Blood Transplantation Is Associated With Superior Disease-Free Survival Due To Reduced Leukemia Relapse. <i>Blood</i> , 2013, 122, 4610-4610.	0.6	0
382	Stem Cell Source Dependent Differences in Reconstituting Peripheral T Follicular Helper Cells Following Hematopoietic Cell Transplantation, Their Association with Chronic Gvhd and Role in Response to Influenza Vaccination. <i>Blood</i> , 2014, 124, 3919-3919.	0.6	0
383	Clonal Expansion of Adaptive NK Cells and NKG2C+CD57+ KIR-Expressing T Cells from Sibling, but Not Umbilical Cord Blood, Grafts Is Induced By Recipient Latent CMV and Is Associated with Protection Against CMV Reactivation. <i>Blood</i> , 2014, 124, 181-181.	0.6	0
384	Day 21 Chimerism Is a Critical Prognostic Factor for Graft Failure and Survival in Recipients of Myeloablative Conditioning and Umbilical Cord Blood (UCB) Transplantation. <i>Blood</i> , 2014, 124, 3867-3867.	0.6	0
385	Pharmacokinetic Modeling of Fludarabine to Control Exposure and Improve Outcomes after Reduced Intensity Conditioning Transplantation. <i>Blood</i> , 2014, 124, 3869-3869.	0.6	0
386	Mitochondrial Haplotype As an Independent Predictor of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2014, 124, 683-683.	0.6	0
387	Risk Factors for Acute and Chronic Gvhd after Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Relative Risks with Umbilical Cord Blood (UCB) and Matched Related Donors (MRD). <i>Blood</i> , 2014, 124, 189-189.	0.6	0
388	Defining Successful Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2015, 126, 1934-1934.	0.6	0
389	Immune Reconstitution (IR) after Allogeneic Hematopoietic Cell Transplantation (alloHCT): Comparing Results in Recipients of Unrelated Umbilical Cord Blood (UCB) to Those with an HLA-Matched Sibling Donor Peripheral Blood (MSD PB). <i>Blood</i> , 2016, 128, 4590-4590.	0.6	0
390	5 Year Health Care Burden after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Impact of Graft Source. <i>Blood</i> , 2018, 132, 367-367.	0.6	0
391	Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. <i>Blood</i> , 2018, 132, 2123-2123.	0.6	0
392	Mgta-456 Contains Large Numbers of Expanded Cord Blood (CB) CD34+CD90+ Hematopoietic Stem Cells (HSC) Which Confer All Engraftment Activity and Correlate with Accelerated Neutrophil Recovery after Myeloablative Conditioning in Patients with Hematologic Malignancy. <i>Blood</i> , 2018, 132, 2083-2083.	0.6	0
393	Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT). <i>Blood</i> , 2019, 134, 2009-2009.	0.6	0
394	Early Engraftment and Lymphocyte Reconstitution Outcomes after Alpha/Beta T Cell Receptor Depletion in Patients Transplanted for Fanconi Anemia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S429.	0.6	0